VBLT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Oct 2023 @ 16:00):

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States...

Stats
Today's Volume	5.38M
Average Volume	787 717
Market Cap	12.11M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.867
ATR14	$0.0180 (11.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Fr Capital Holdings, L.p.	Sell	50 000	Ordinary Shares, par value NIS 0.35 each
2023-12-28	Fr Capital Holdings, L.p.	Sell	21 500	Ordinary Shares, par value NIS 0.35 each
2023-12-29	Fr Capital Holdings, L.p.	Sell	6 000	Ordinary Shares, par value NIS 0.35 each
2023-12-26	Fr Capital Holdings, L.p.	Sell	11 456	Ordinary Shares, par value NIS 0.35 each
2023-12-27	Fr Capital Holdings, L.p.	Sell	20 033	Ordinary Shares, par value NIS 0.35 each

INSIDER POWER
-42.85
Last 32 transactions
Buy: 525 000 \| Sell: 1 196 932

Volume Correlation

Long: 0.12 (neutral)

Short: -0.68 (moderate negative)

Signal:(31.998) Neutral

Vascular Biogenics Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vascular Biogenics Ltd Correlation - Currency/Commodity

-0.46
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.40
( neutral )

0.38
( neutral )

Vascular Biogenics Ltd Financials

Annual	2022
Revenue:	$658 000
Gross Profit:	$554 000 (84.19 %)
EPS:	$-0.420

FY	2022
Revenue:	$658 000
Gross Profit:	$554 000 (84.19 %)
EPS:	$-0.420

FY	2021
Revenue:	$768 000
Gross Profit:	$403 000 (52.47 %)
EPS:	$-0.685

FY	2020
Revenue:	$922 000
Gross Profit:	$528 000 (57.27 %)
EPS:	$-0.550

Financial Reports:

No articles found.

Vascular Biogenics Ltd

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.